查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853597

内视镜逆行性造影市场按手术类型、产品类型、应用和最终用户划分 - 全球预测 2025-2032

Endoscopic Retrograde Cholangiopancreatography Market by Procedure Type, Product, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，内视镜逆行性造影市场规模将达 37.7 亿美元，复合年增长率为 7.86%。

关键市场统计数据
基准年2024年 20.5亿美元
预计年份：2025年 22.1亿美元
预测年份 2032 37.7亿美元
复合年增长率（%） 7.86%

全面介绍现代ERCP生态系统，重点阐述其临床应用范围、器材类别以及诊断与治疗的交叉领域。

内视镜逆行性造影）仍是肝胆胰疾病诊疗中诊断影像和治疗性介入相结合的基石技术。近年来，该技术已从以诊断为重点的造影发展成为以治疗主导的技术，强调括约肌切开术、支架置入术和取石术等标靶干预。随着临床实践向微创内视镜解决方案转变，临床医生和采购人员都需要清楚地了解技术进步、最佳操作规范以及影响其应用和疗效的各种动态。

本执行摘要概述了现代ERCP实践及其配套器械生态系统的关键主题。透过分析内视镜系统、影像处理辅助设备（如光源和视讯处理器）以及整体配件的进展，本概要描绘了临床创新的发展轨迹，并兼顾了安全性、培训和供应链韧性等实际考虑。内容涵盖胆道疾病（包括胆结石、胆漏和胆道狭窄）和胰臟疾病（包括胰臟炎和胰臟肿瘤），反映了ERCP广泛的临床应用范围。

读者将从中获得兼顾流程细节和策略远见的综合观点。本书旨在帮助临床医生、医疗系统采购负责人和医疗器材创新者做出明智的选择，使临床疗效与营运实际情况、监管限制以及不断变化的支付方期望相契合。贯穿全书的过渡性说明重点阐述如何利用科技差异化来减少不利事件、提高病患週转率并提升医疗品质。

找出正在改变 ERCP 实践的关键变革性转变，包括增强影像技术、采用单次胆道镜检查以及辅助设备创新。

内视镜逆行性胰胆管摄影术（ERCP）领域正经历变革时期，主要得益于影像技术、单孔胆道镜器械以及辅助设备创新技术的同步发展。现代视讯处理器和优化光源的运用显着提升了可视化效果，提高了病灶检出率和手术精准度；而单孔胆道镜系统的日益成熟，则拓展了直接可视化能力，从而支持靶向碎石和组织取样。这些技术主导的变革也得益于辅助设备的改进设计，例如更灵活的导管导引线、精密的括约肌切开刀以及旨在提高输送性能和减少组织反应的支架平台。

同时，临床实践正朝着治疗为主的方向发展，内视镜医师在临床适宜的情况下更倾向于微创手术而非外科手术。越来越多的证据支持优化手术安全性，进一步强化了这个临床方向。预防术后胰臟炎的策略，例如使用直肠非类固醇消炎剂和选择性胰管支架置入术，已成为许多诊疗路径的标准组成部分。训练和模拟也不断扩展，以帮助操作者熟悉复杂的手术流程和新设备，从而加速安全应用。

供应链多元化以及影像和内视镜平台间互通性的追求，代表着系统性的进一步变革。为了在确保临床疗效的同时精简库存，医院和门诊中心越来越重视能够跨临床环境提供稳定性能的模组化系统和配件。总而言之，这些转变正在显着改变医疗机构优先考虑资本投资、设计临床工作流程以及与製造商合作开发符合不断发展的护理标准的解决方案的方式。

评估美国关税调整至2025年对ERCP器械供应链、筹资策略和临床准入的累积影响

在美国，一系列将于2025年之前实施的关税政策正对医疗设备供应链施加累积压力，需要製定周密的战略应对措施。某些零件和成品的进口关税提高，推高了内视镜系统、影像处理平台和精密配件的到岸成本。因此，采购团队必须在有限的资本预算和对先进技术的临床需求之间取得平衡，并优先考虑临床影响和整体拥有成本，而不仅仅是单位成本。

製造商和经销商正采取多样化的筹资策略来应对挑战，包括将部分製造、组装和零件生产转移到其他地区，以降低对关税敏感的供应链的风险。虽然靠近终端市场可以缩短前置作业时间并减轻跨境关税的影响，但也可能需要新的资本投资、监管核准和劳动力发展。此外，一些供应商正在调整产品系列，更加重视国内生产的零件和受关税分类影响较小的替代材料，从而保持净利率并维持市场进入。

临床医生和医疗系统已调整采购行为，深化与供应商在定价模式、批量采购和服务水平协议方面的合作，以应对关税造成的部分成本波动。同时，人们对现有内视镜和成像平台的改装和模组化升级策略越来越感兴趣，希望在不进行全面资本更换的情况下延长其使用寿命。最终，到2025年，关税环境的累积凸显了临床、供应链和财务相关人员之间开展跨职能规划的必要性，以在控製成本波动的同时，确保临床创新成果的持续应用。

基于深度细分的洞察揭示了手术类型、产品架构、临床应用和医疗环境如何决定ERCP的采用和采购。

深入的市场区隔揭示了手术决策、产品架构、临床适应症和医疗环境如何相互交织，共同塑造器材的使用和创新路径。基于手术类型，市场研究分为诊断和治疗两大类。诊断方面，我们进一步探讨了造影和造影；治疗方面，我们进一步探讨了括约肌切开术、支架置入术和取石术。区分这些手术至关重要，因为诊断流程优先考虑影像保真度和易用性，而治疗流程则需要耐用的配件、可靠的支架输送系统以及针对取石和组织操作优化的工具。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 增加一次性十二指肠镜的使用，以降低交叉感染风险
  • 先进数位胆道镜平台在标靶胆道介入治疗的应用日益广泛
  • 人工智慧驱动的影像分析技术在ERCP术中即时病灶检测的进展
  • 开发一种非侵入性导管导引线系统，以提高复杂解剖结构插管的成功率
  • 混合式 ERCP超音波检查的需求日益增长，这种检查可以将诊断和治疗结合在一次检查中完成。
  • 扩充包含扩增实境的训练模拟模组，以提升ERCP技能

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依手术类型分類的内视镜逆行性造影市场

  • 诊断
    • 造影
    • 胰臟造影
  • 治疗
    • 括约肌切开术
    • 支架置入
    • 石材开采

9. 内视镜逆行性造影市场（依产品划分）

  • 配件
  • 内视镜系统
  • 影像系统
    • 光源
    • 视讯处理器

第十章 内视镜逆行性造影市场（依应用领域划分）

  • 胆道疾病
    • 胆结石
    • 洩漏
    • 收缩
  • 胰臟疾病
    • 胰臟炎
    • 瘤

第十一章 内视镜逆行性造影市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 专科诊所

12. 内视镜逆行性造影市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 内视镜逆行性造影市场（依组别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国内镜逆行造影市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Olympus Corporation
    • Boston Scientific Corporation
    • Medtronic plc
    • Fujifilm Holdings Corporation
    • HOYA Corporation
    • KARL STORZ SE & Co. KG
    • Cook Medical LLC
    • CONMED Corporation
    • Ambu A/S
    • Stryker Corporation
Product Code: MRR-5A2C6AA6657B

The Endoscopic Retrograde Cholangiopancreatography Market is projected to grow by USD 3.77 billion at a CAGR of 7.86% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.05 billion
Estimated Year [2025] USD 2.21 billion
Forecast Year [2032] USD 3.77 billion
CAGR (%) 7.86%

Comprehensive introduction to the contemporary ERCP ecosystem highlighting clinical scope, device categories, and the intersection of diagnostic and therapeutic practice

Endoscopic retrograde cholangiopancreatography remains a cornerstone procedure at the interface of diagnostic imaging and therapeutic intervention within hepatobiliary and pancreatic care. Over recent years, the procedure has evolved from principally diagnostic cholangiography and pancreatography into a therapy-driven modality emphasizing targeted interventions such as sphincterotomy, stent placement, and stone extraction. As clinical practice pivots toward minimally invasive endoscopic solutions, practitioners and procurement professionals alike require a clear synthesis of technological advances, procedural best practices, and the shifting dynamics that influence adoption and outcomes.

This executive summary consolidates essential themes that define contemporary ERCP practice and the device ecosystem that supports it. By examining advances in endoscope systems, imaging adjuncts such as light sources and video processors, and the full complement of accessories, the analysis maps the trajectory of clinical innovation alongside practical considerations of safety, training, and supply chain resilience. Importantly, the content addresses both biliary system disorders including gallstones, leaks, and strictures, and pancreatic system disorders such as pancreatitis and tumors, reflecting the broad clinical footprint of ERCP.

Readers will find an integrated perspective that balances procedural detail with strategic foresight. The aim is to enable clinicians, health-system procurement leaders, and device innovators to make informed choices that align clinical efficacy with operational realities, regulatory constraints, and evolving payer expectations. Transitional commentary throughout this document highlights opportunities to reduce adverse events, improve patient throughput, and leverage technological differentiation to advance care quality.

Identifying the major transformative shifts altering ERCP practice including imaging enhancements, single-operator cholangioscopy adoption, and accessory innovation

The ERCP landscape is undergoing transformative shifts driven by parallel advances in imaging, single-operator cholangioscopy, and accessory innovation. Enhanced visualization provided by modern video processors and optimized light sources has improved lesion detection and procedural precision, while the maturation of single-operator cholangioscopy systems has expanded direct-visualization capabilities that support targeted lithotripsy and tissue acquisition. These technology-led changes are complemented by improvements in accessory design including more flexible guidewires, refined sphincterotomes, and stent platforms engineered for deliverability and reduced tissue reaction.

Concurrently, clinical practice has trended toward therapeutic-first approaches in many indications, with endoscopists increasingly favoring minimally invasive interventions over surgical alternatives when clinically appropriate. This clinical pivot is reinforced by growing evidence for procedural safety optimization, with prophylactic strategies against post-procedure pancreatitis such as rectal nonsteroidal anti-inflammatory drug use and selective pancreatic stenting becoming standard components of many care pathways. Training and simulation have also expanded, supporting operator proficiency in complex maneuvers and new device utilization, thereby accelerating safe adoption.

Supply chain diversification and the pursuit of interoperability across imaging and endoscope platforms represent additional systemic shifts. As hospitals and ambulatory centers seek to streamline inventories while ensuring clinical efficacy, there is greater emphasis on modular systems and accessories that deliver consistent performance across a range of clinical settings. Taken together, these shifts are reshaping how institutions prioritize capital investments, design clinical workflows, and partner with manufacturers to co-develop solutions that align with evolving standards of care.

Assessing the cumulative impact of tariff shifts in the United States through 2025 on ERCP device supply chains, procurement strategies, and clinical access

In the United States, tariff policies enacted through 2025 have exerted cumulative pressures on the medical device supply chain that warrant careful strategic response. Increased import duties on selected components and finished devices have elevated landed costs for endoscope systems, imaging platforms, and high-precision accessories. As a result, procurement teams must reconcile the clinical imperative of advanced technology adoption with constrained capital budgets, prompting prioritization exercises that emphasize clinical impact and total cost of ownership rather than unit price alone.

Manufacturers and distributors have responded with diversified sourcing strategies, relocating portions of manufacturing, assembly, or component production to mitigate exposure to tariff-sensitive supply lines. This re-shoring and near-shoring activity has introduced both opportunities and complexities: while proximity to end markets can shorten lead times and reduce exposure to cross-border duties, it may also necessitate new capital investments, regulatory approvals, and workforce training. Moreover, some suppliers have shifted product portfolios to emphasize domestically manufactured components or alternative materials that are less affected by tariff classifications, enabling continued market access while preserving margins.

Clinicians and health systems have adapted procurement behavior by increasing collaboration with vendors on pricing models, bundled purchasing, and service-level agreements that absorb parts of tariff-driven cost variability. In parallel, there has been greater interest in retrofit and modular upgrade strategies for existing endoscope and imaging platforms to extend usable lifecycles without full capital replacement. Ultimately, the cumulative tariff environment through 2025 has reinforced the imperative for cross-functional planning among clinical, supply chain, and finance stakeholders to preserve access to clinical innovations while managing cost volatility.

Deep segmentation-driven insights revealing how procedure type, product architecture, clinical application, and care setting jointly determine ERCP adoption and procurement

Insightful segmentation clarifies how procedural decision-making, product architecture, clinical indication, and care setting intersect to shape device utilization and innovation pathways. Based on Procedure Type, market is studied across Diagnostic and Therapeutic; the Diagnostic is further studied across Cholangiography and Pancreatography while the Therapeutic is further studied across Sphincterotomy, Stent Placement, and Stone Extraction. These procedural distinctions matter because diagnostic workflows prioritize imaging fidelity and maneuverability, whereas therapeutic workflows demand durable accessories, reliable stent delivery systems, and tools optimized for extraction and tissue manipulation.

Based on Product, market is studied across Accessories, Endoscope Systems, and Imaging Systems; the Imaging Systems is further studied across Light Sources and Video Processors. Product segmentation highlights the layered nature of procurements where core capital equipment investments in endoscope systems and imaging platforms are paired with high-turnover accessory portfolios that influence recurring spend and clinical throughput. Accessories often drive procedure-level performance metrics, and their compatibility with legacy systems is a common determinant of purchasing decisions.

Based on Application, market is studied across Biliary System Disorders and Pancreatic System Disorders; the Biliary System Disorders is further studied across Gallstones, Leaks, and Strictures while the Pancreatic System Disorders is further studied across Pancreatitis and Tumors. Application-based segmentation underscores the clinical drivers of device selection, as the management of gallstones or strictures may prioritize lithotripsy-capable platforms and stent technology, while tumor-related indications often require enhanced imaging, biopsy capability, and multidisciplinary coordination. Finally, based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics. End-user segmentation reflects variability in capital budgets, case complexity, and throughput expectations, with ambulatory centers focusing on efficiency and cost control, hospitals balancing high-acuity caseloads with teaching and research imperatives, and specialty clinics emphasizing niche expertise and longitudinal patient management.

Key regional dynamics and adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape ERCP deployment and supply chain strategies

Regional dynamics influence technology adoption, clinical practice patterns, and supply chain configurations in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, consolidation among health systems and a strong emphasis on value-based care are driving demand for devices that demonstrate procedural efficiency and measurable outcomes, while centers of excellence in tertiary hospitals continue to serve as early adopters of advanced cholangioscopy and lithotripsy technologies. Regional payer structures also influence procurement timing and the appetite for bundled purchasing or capital leasing arrangements that optimize cash flow.

Within Europe, the Middle East & Africa, heterogeneity in regulatory regimes and healthcare funding models creates a mosaic of adoption rates. Some countries with centralized procurement favor standardized platforms that can be deployed broadly, whereas others prioritize innovation within leading academic centers. In several EMEA markets, efforts to expand minimally invasive care pathways are stimulating interest in training programs and partnerships that accelerate operator skill acquisition, thus creating a pipeline for broader device uptake.

Asia-Pacific presents a highly dynamic environment where rapid clinical capacity expansion and large patient volumes have spurred investment in both capital equipment and workforce development. High-volume centers in major metropolitan areas often pioneer new procedural workflows and leverage scale to negotiate favorable procurement terms. Simultaneously, regional manufacturing hubs and component suppliers have become important nodes in the global supply chain, affecting availability and pricing of accessories and replacement parts. Across all regions, cross-border collaboration, regulatory harmonization efforts, and clinical evidence generation continue to shape how devices are evaluated and adopted in practice.

Company-level dynamics highlighting innovation in endoscopes, imaging platforms, accessory design, and strategic partnerships that accelerate clinical adoption

A focused set of manufacturers, clinical innovators, and technology integrators are driving the current evolution of ERCP tools and supporting ecosystems. Leading endoscope and imaging platform providers have invested in higher-resolution video processors and optimized light sources to improve diagnostic clarity and procedural confidence. Concurrently, accessory specialists have concentrated on developing more deliverable stent systems, low-trauma sphincterotomes, and efficient stone extraction tools that reduce procedure time and complication risk. These product-level innovations are frequently paired with enhanced training programs, service offerings, and data-driven support to facilitate adoption.

Strategic partnerships between device firms and clinical centers have become more common, accelerating real-world evidence collection and enabling iterative product refinement. In addition, manufacturers are increasingly offering bundled service and maintenance programs that reduce total lifecycle costs and provide predictable budgeting for end users. Distribution partners and system integrators play a pivotal role in ensuring compatibility between endoscope systems and third-party imaging modules, and they often contribute to after-sales training and support which are critical for complex therapeutic procedures.

Finally, newer entrants and niche innovators focusing on cholangioscopy-guided lithotripsy, biodegradable stents, and single-use accessory concepts are reshaping competitive dynamics. Their presence encourages incumbents to improve product differentiation and to expand clinical studies that demonstrate tangible improvements in safety or efficiency. Collectively, these company-level trends underscore a market where clinical credibility, service excellence, and interoperability are central to commercial success.

Actionable recommendations for industry leaders to align product design, clinical evidence, and supply chain resilience to accelerate adoption and deliver measurable value

Industry leaders should adopt a multi-pronged strategy that aligns product innovation, clinical evidence generation, and supply chain resilience to sustain competitive advantage and improve patient outcomes. First, prioritizing modular and interoperable system architectures will allow institutions to upgrade imaging or processing components without replacing entire endoscope platforms, thereby reducing capital barriers to adopting advanced visualization. Investing in accessories that are backward-compatible with legacy systems can also expand addressable markets and ease procurement decisions.

Second, companies and health systems should co-invest in robust clinical evidence programs that measure not only immediate procedural outcomes but also longitudinal metrics such as reintervention rates, health-economic impact, and patient-reported outcomes. These data will be critical to justify adoption in value-conscious purchasing environments and to support payer engagement. Third, developing tariff-mitigation strategies such as diversified sourcing, near-shoring critical component production, and transparent pricing models will reduce exposure to policy-driven cost variability and improve supply predictability.

Fourth, expanding operator training and simulation offerings will both speed safe adoption of advanced techniques and reduce complication rates that can erode confidence in new technologies. Finally, adopting outcome-based contracting and bundled-service models can align incentives between manufacturers, providers, and payers, promoting broader access to innovations while sharing the financial risk of new technology deployment.

Robust mixed-methods research methodology combining expert interviews, clinical literature review, and practical scenario mapping to validate ERCP trends and implications

The analysis underpinning this executive summary synthesizes a structured research approach that blends primary stakeholder engagement with comprehensive secondary review of clinical and regulatory sources. Primary research included interviews with practicing endoscopists, hospital procurement leaders, specialty clinic administrators, and device OEM representatives to capture current adoption patterns, unmet needs, and procurement decision drivers. These conversations were augmented by procedural observations and input from clinical educators to validate assumptions about training requirements and workflow integration.

Secondary research incorporated peer-reviewed clinical literature, regulatory filings, device labeling, and publicly available procedural guidelines to ensure technical accuracy and alignment with contemporary clinical practice. Where appropriate, registries and procedural outcome datasets were canvassed to corroborate trends in complication mitigation strategies and device utilization. Attention was given to recent advances in imaging technology, single-operator cholangioscopy modalities, and accessory-driven innovations to reflect the most relevant developments influencing clinical decision-making.

Analytical methods included thematic synthesis of qualitative inputs and triangulation across sources to identify consistent patterns and strategic implications. The methodology also entailed scenario mapping to assess the operational impacts of supply chain disruptions and tariff-related cost shifts, enabling practical recommendations that are responsive to both clinical and commercial realities.

Conclusive synthesis of ERCP strategic imperatives emphasizing technology, clinical evidence, and collaborative approaches to advance care and manage cost pressures

In sum, the ERCP landscape is characterized by rapid technological refinement, procedural shifts toward therapeutic-first care, and evolving procurement dynamics shaped by regional policy and tariff influences. Improved imaging, the rise of single-operator cholangioscopy, and accessory innovation are collectively enhancing the efficacy and scope of endoscopic interventions for biliary and pancreatic disorders. These clinical and technological drivers are occurring alongside heightened attention to procedural safety, operator training, and interoperable system architectures that support sustainable adoption.

Going forward, stakeholders who successfully integrate clinical evidence, flexible product design, and supply chain strategies will be best positioned to deliver improved patient outcomes while managing cost and access pressures. Collaboration among device manufacturers, clinical centers, and payers will be essential to translate incremental innovations into measurable clinical and economic value. By focusing on interoperability, lifecycle cost management, and outcome-oriented contracting, organizations can navigate current headwinds and seize opportunities to expand the role of ERCP in minimally invasive hepatobiliary and pancreatic care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of single-use disposable duodenoscopes to mitigate cross-contamination risks
  • 5.2. Increased utilization of advanced digital cholangioscopy platforms for targeted biliary interventions
  • 5.3. Advancements in artificial intelligence driven image analysis for real-time lesion detection during ERCP
  • 5.4. Development of atraumatic guidewire systems to improve cannulation success rates in complex anatomy
  • 5.5. Rising demand for hybrid ERCP endoscopic ultrasound procedures to combine diagnosis and therapy in single session
  • 5.6. Expansion of training simulation modules incorporating augmented reality to expedite ERCP proficiency acquisition

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endoscopic Retrograde Cholangiopancreatography Market, by Procedure Type

  • 8.1. Diagnostic
    • 8.1.1. Cholangiography
    • 8.1.2. Pancreatography
  • 8.2. Therapeutic
    • 8.2.1. Sphincterotomy
    • 8.2.2. Stent Placement
    • 8.2.3. Stone Extraction

9. Endoscopic Retrograde Cholangiopancreatography Market, by Product

  • 9.1. Accessories
  • 9.2. Endoscope Systems
  • 9.3. Imaging Systems
    • 9.3.1. Light Sources
    • 9.3.2. Video Processors

10. Endoscopic Retrograde Cholangiopancreatography Market, by Application

  • 10.1. Biliary System Disorders
    • 10.1.1. Gallstones
    • 10.1.2. Leaks
    • 10.1.3. Strictures
  • 10.2. Pancreatic System Disorders
    • 10.2.1. Pancreatitis
    • 10.2.2. Tumors

11. Endoscopic Retrograde Cholangiopancreatography Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Endoscopic Retrograde Cholangiopancreatography Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Endoscopic Retrograde Cholangiopancreatography Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Endoscopic Retrograde Cholangiopancreatography Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Olympus Corporation
    • 15.3.2. Boston Scientific Corporation
    • 15.3.3. Medtronic plc
    • 15.3.4. Fujifilm Holdings Corporation
    • 15.3.5. HOYA Corporation
    • 15.3.6. KARL STORZ SE & Co. KG
    • 15.3.7. Cook Medical LLC
    • 15.3.8. CONMED Corporation
    • 15.3.9. Ambu A/S
    • 15.3.10. Stryker Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET S